SOX15

SOX15 is an HMG-box transcription factor that regulates cell fate decisions across myogenic, pluripotent, epithelial, and germ cell lineages by binding SOX consensus DNA sequences and partnering with context-specific co-factors. It associates with OCT3/4 on octamer-SOX composite elements in embryonic stem cells to regulate pluripotency-associated genes such as Hrc and the Hes5 enhancer, cooperates with Fhl3 to activate Foxk1 in myogenic progenitors required for satellite cell maintenance and skeletal muscle regeneration, and enhances Hand1-driven transcription during trophoblast differentiation (PMID:15863505, PMID:17363903, PMID:16759287, PMID:36764520). SOX15 functions as a tumor suppressor in multiple cancers—including pancreatic, thyroid, ovarian, and prostate malignancies—by suppressing Wnt/β-catenin signaling and by directly repressing MMP2 or activating AOC1 to promote ferroptosis, and its expression is silenced by promoter hypermethylation, homozygous deletion, or post-transcriptionally by miR-147b and miR-1294 targeting its 3′UTR (PMID:23318427, PMID:31760045, PMID:40833191, PMID:35922412). SOX15 protein levels are regulated post-translationally through MKRN1-mediated ubiquitination and proteasomal degradation, a process facilitated by the circular RNA scaffold circVPS8 in glioblastoma (PMID:39098847).

1. 2000 High

   Establishing SOX15 as a DNA-binding transcription factor with a functional role in myogenesis: SOX15 was shown to bind SOX consensus DNA and, through its C-terminal transactivation domain, inhibit muscle-specific gene activation when overexpressed in myoblasts, revealing it as a modulator of the myogenic transcriptional program.

   Evidence EMSA for DNA binding, C-terminal truncation mutant, overexpression in C2C12 myoblasts with myogenin/MyoD readout

   PMID:10821863

   Open questions at the time

   • Overexpression-only design; endogenous function not yet addressed
   • Whether the repressive effect reflects a physiological role or is an artifact of forced expression was unresolved
2. 2004 High

   Genetic loss-of-function confirmed that endogenous Sox15 is required for normal myoblast differentiation and skeletal muscle regeneration, and distinguished its role from other MRFs by showing reciprocal regulation of MyoD and Myf5.

   Evidence Sox15 knockout mouse, in vitro differentiation assay, crush injury model, RT-PCR

   PMID:15367664

   Open questions at the time

   • Direct transcriptional targets mediating the regeneration defect were unknown
   • Whether Sox15 acts in satellite cells specifically was not determined
3. 2005 High

   SOX15's partnership with OCT3/4 and its direct DNA target Hrc were identified, placing SOX15 within the pluripotency transcription factor network and establishing it as a weaker-affinity SOX2 paralogue on composite SOX-octamer elements.

   Evidence EMSA, SELEX, ChIP at Hrc promoter, DNA microarray in mouse ES cells

   PMID:15863505

   Open questions at the time

   • Functional redundancy with SOX2 in pluripotency not directly tested
   • Genome-wide target map in ES cells was lacking
4. 2006 High

   Discovery that SOX15 physically interacts with Hand1 and enhances its transcriptional activity expanded SOX15's role beyond myogenesis to trophoblast differentiation, demonstrating co-factor-dependent functional diversity.

   Evidence Co-immunoprecipitation in 293T cells, in vitro binding, luciferase reporter with domain mapping

   PMID:16759287

   Open questions at the time

   • Endogenous relevance in placental tissue not shown
   • Whether Hand1-SOX15 co-regulate specific genomic loci was unresolved
5. 2007 High

   SOX15 was shown to directly activate Foxk1 transcription by binding its promoter with co-activator Fhl3, and Sox15-mutant mice displayed reduced satellite cell numbers, establishing the molecular mechanism by which SOX15 maintains the myogenic progenitor pool.

   Evidence ChIP at Foxk1 promoter, transgenic reporter, knockdown, Sox15 mutant mouse satellite cell quantification

   PMID:17363903

   Open questions at the time

   • Whether Foxk1 restoration rescues the satellite cell defect was not tested
   • Mechanism linking SOX15-Foxk1 axis to cell cycle regulation in satellite cells was incomplete
6. 2009 Medium

   SOX15 was shown to be sufficient and necessary for muscle precursor cell fate acquisition—upregulating Pax3/7 and Meox1 while blocking premature MyoD expression—clarifying that SOX15 acts at the progenitor stage rather than during terminal differentiation.

   Evidence Stable SOX15 expression and dominant-negative in P19 cells, gene expression analysis

   PMID:19489079

   Open questions at the time

   • P19 embryonal carcinoma cells may not fully recapitulate normal myogenesis
   • Direct targets mediating Pax3/7 upregulation not identified
7. 2013 Medium

   SOX15 was identified as a candidate tumor suppressor in pancreatic cancer, silenced by homozygous deletion and promoter hypermethylation, with functional restoration reducing viability and suppressing Wnt/β-catenin signaling—extending SOX15 biology from development to cancer.

   Evidence Re-expression in pancreatic cancer cell lines, xenograft, Wnt pathway assay, methylation profiling

   PMID:23318427

   Open questions at the time

   • Direct mechanism by which SOX15 suppresses Wnt signaling was not defined
   • No patient cohort survival analysis provided
8. 2015 High

   Genome-wide ChIP-seq revealed SOX15 as a lineage-specific transcriptional regulator of squamous epithelial identity, demonstrating that its binding is enriched near esophagus-expressed genes and is required for their transcription—expanding SOX15's tissue repertoire beyond muscle and ES cells.

   Evidence ChIP-seq, siRNA knockdown with transcriptome analysis in human esophageal cells

   PMID:26516633

   Open questions at the time

   • Whether SOX15 loss causes squamous epithelial pathology in vivo was not tested
   • Co-factors mediating esophageal specificity were not identified
9. 2017 Medium

   In Xenopus, the SOX15 orthologue SoxD was shown to directly bind Hesx1/Xanf1 protein and co-occupy its promoter, counteracting auto-repression and thereby maintaining forebrain gene expression—providing evidence for a conserved role in anterior neural patterning.

   Evidence GST pull-down, EMSA, luciferase reporter in Xenopus

   PMID:28918251

   Open questions at the time

   • Conservation of this mechanism in mammalian forebrain not demonstrated
   • Orthology between Xenopus SoxD and mammalian SOX15 is supported but not definitive
10. 2019 Medium

    Post-transcriptional regulation of SOX15 was established: miR-147b directly targets the SOX15 3′UTR to suppress its expression, thereby activating Wnt/β-catenin signaling and promoting thyroid carcinoma growth, while SOX15 overexpression reverses this effect.

    Evidence Luciferase 3′UTR reporter, overexpression/knockdown, Wnt pathway Western blot, xenograft

    PMID:31760045

    Open questions at the time

    • Whether SOX15 directly binds Wnt pathway gene promoters or acts indirectly remains unclear
    • Single lab; independent replication in thyroid cancer not reported
11. 2019 Medium

    SOX15 was demonstrated to maintain human primordial germ cell-like cell identity after specification, using acute protein depletion and overexpression, distinguishing it from specification factors and suggesting partial functional compensation by PRDM14.

    Evidence Auxin-inducible degron depletion, ProteoTuner overexpression, flow cytometry in hPGCLC model

    PMID:31583280

    Open questions at the time

    • Direct transcriptional targets in germ cells not identified
    • PRDM14 compensation hypothesis based on qPCR only
12. 2020 Medium

    SOX15's role in reprogramming was further refined: co-expression with ASF1A and OCT4 generated iPSCs with a distinctive pluripotent state and higher differentiation capacity than standard Yamanaka iPSCs, indicating SOX15 engages a mechanistically distinct reprogramming pathway.

    Evidence Human somatic cell reprogramming, iPSC derivation, molecular profiling

    PMID:32738616

    Open questions at the time

    • Molecular basis distinguishing SOX15-mediated from SOX2-mediated reprogramming not delineated
    • Whether this alternative pluripotent state is stable long-term was not assessed
13. 2022 Medium

    A new tumor-suppressive mechanism was uncovered: SOX15 transcriptionally activates AOC1, which metabolizes spermidine to generate ROS and induce ferroptosis in prostate cancer cells, linking SOX15 to metabolic cell death pathways.

    Evidence SOX15 overexpression/knockdown, AOC1 expression analysis, ROS assay, in vitro and in vivo proliferation assays

    PMID:35922412

    Open questions at the time

    • Direct ChIP evidence for SOX15 binding at the AOC1 promoter not shown
    • Whether the ferroptosis link operates in other SOX15-expressing tissues is unknown
14. 2023 High

    SOX15 was shown to contribute to ES cell pluripotency independently of SOX2 and to promote neural differentiation by directly binding a distal Hes5 enhancer, resolving its non-redundant role in the SOX family pluripotency network.

    Evidence SOX15 depletion/overexpression in ESCs, reprogramming assay, ChIP at Hes5 enhancer, neural differentiation

    PMID:36764520

    Open questions at the time

    • Full set of SOX15-specific versus SOX2-shared targets not catalogued
    • Structural basis for SOX15-specific enhancer selectivity unknown
15. 2024 Medium

    Post-translational regulation of SOX15 was elucidated: MKRN1-mediated ubiquitination targets SOX15 for proteasomal degradation, scaffolded by circVPS8 in glioblastoma, with SOX15 depletion cooperating with HNF4A elevation to suppress ferroptosis in glioblastoma stem cells.

    Evidence Co-immunoprecipitation, ubiquitination assay, siRNA, in vivo glioblastoma model

    PMID:39098847

    Open questions at the time

    • Whether MKRN1-SOX15 ubiquitination occurs outside the glioblastoma context is unknown
    • Specific lysine residues on SOX15 targeted for ubiquitination not identified
16. 2025 Medium

    SOX15 was shown to directly bind the MMP2 promoter and repress its transcription, thereby suppressing vasculogenic mimicry in ovarian cancer—adding a specific anti-metastatic transcriptional target to SOX15's tumor-suppressive repertoire.

    Evidence ChIP-PCR, dual-luciferase reporter, overexpression/knockdown, xenograft

    PMID:40833191

    Open questions at the time

    • Whether MMP2 repression is a general SOX15 function across cancer types is untested
    • Mechanism by which SOX15 represses (rather than activates) this particular promoter is unclear

• Key unresolved questions include: the structural basis for SOX15's weaker DNA-binding affinity relative to SOX2 and its distinct enhancer selectivity; the direct mechanism by which SOX15 suppresses Wnt/β-catenin signaling; genome-wide maps of SOX15 targets across its diverse tissue contexts (muscle, germ cells, esophagus, tumors); and the physiological regulation of SOX15 protein turnover beyond glioblastoma.
• No crystal structure of SOX15 HMG domain–DNA complex
• Direct Wnt pathway target genes of SOX15 unidentified
• No integrative multi-tissue SOX15 cistrome